News Detail

New Delhi, 2 March 2024: The Indian health regulator now requires more information if any changes are made to the manufacturing processes of biological drugs in India once they have been approved for marketing, it is learnt.
To bolster the production of biological drug......
View Details
Source : News 18
Drug Controller General of India
DCGI
WHO
schedule M
Related News
- Critical medicines for cancer, diabetes set to get expensive as govt clears price hike, say sources (27-03-2025)
- DGFT proposes mandatory GST E-Invoices for pharma export benefits (27-03-2025)
- US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome (27-03-2025)
- FDA approves GSK’s 'Blujepa' for uncomplicated UTIs (27-03-2025)
- Bengal drug control publishes helpline to report fake medicines (27-03-2025)
- Misleading ads: SC asks states UTs to set up grievance redressal mechanism (26-03-2025)
- WHO partners with regulators, experts to strengthen safety and access of medical devices (26-03-2025)
- PCI warns of tough action against inspectors who don't follow its guidelines during inspection (26-03-2025)
- Seizure of fake Human Albumin Vials rings alarm bells (26-03-2025)
- Pharmacy owner, three others held for illegal sale of intoxication drug (26-03-2025)